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Abstract
Background: People with chronic health conditions are known to have a higher prevalence of depressive disorder.
The Patient Health Questionnaire (PHQ-9) is a widely-used screening tool for depression which has not yet been
validated for use on chronic care patients in South Africa.
Methods: A sample of 676 chronic care patients attending two primary health facilities in North West Province, South
Africa were administered the PHQ-9 by field workers and a diagnostic interview (the Structured Clinical Interview for
DSM-IV) (SCID) by clinical psychologists. The PHQ-9 and the PHQ-2 were evaluated against the SCID, as well
as for sub-samples of patients who were being treated for HIV infection and for hypertension.
Results: Using the SCID, 11.4 % of patients had major depressive disorder. The internal consistency estimate
for the PHQ-9 was 0.76, with an area under the receiver operator curve (AUROC) of 0.85 (95 % CI 0.82–0.88),
which was higher than the AURUC for the PHQ-2 (0.76, 95 % CI 0.73–0.79). Using a cut-point of 9, the PHQ-9
has sensitivity of 51 % and specificity of 94 %. The PHQ-9 AUROC for the sub-samples of patients with HIV
and with hypertension were comparable (0.85 and 0.86, respectively).
Conclusions: The PHQ-9 is useful as a screening tool for depression among patients receiving treatment for
chronic care in a public health facility.
Keywords: Questionnaire (PHQ-9), Validation studies, Depressive disorder, Chronic disease, South Africa,
Mass screening, Diagnosis
Background
An estimated 14 % of the global burden of disease can
be attributed to neuropsychiatric disorders, primarily
related to the disabling nature of depression and other
common mental disorders [1, 2]. Depression has also
been found to be co-morbid with a range of chronic
diseases, including HIV/AIDS [3, 4] cardiovascular
disorder (CVD) and diabetes [1, 5]. Large studies have
shown that patients with chronic obstructive pulmonary
disease, chronic renal failure and cerebrovascular disease
compared with age-matched healthy controls were
almost three times more likely to have depression, and
twice as likely for patients with diabetes or hypertension
[6, 7]. The WHO World Mental Health Survey in
developed and developing countries [8] and the review
of the evidence by the National Institute for Health and
Clinical Excellence (NICE) guidance for depression in
adults with a chronic physical health problem reports
similar findings [9].
The co-morbidity of depression with chronic condi-
tions is a public health concern due to their mutual
reinforcement and synergistic clinical effects [7, 10, 11].
Evidence for the reciprocal relationship between depres-
sion and chronic physical health problems suggests a
number of causal pathways, including emotional distress
and poor sleep due to pain [12], the prospect of disabil-
ity, [1] and changes in allostatic load whereby the ability
of the body to adapt may be compromised due to
ongoing tissue damage and degenerative changes [9].
Similarly, depression can also contribute to the
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development of physical health problems. Systematic
reviews of 11 prospective cohort studies in health popula-
tions reveal that depression predicts later development of
coronary heart disease [13] and stroke. Furthermore,
major depressive disorder (MDD) can act as a precipitant
for HIV infection as well be a consequence of HIV infec-
tion [14, 15]. One third of HIV-infected patients were
found to be depressed in a recent screening study for
depression in a high HIV burden primary health care
clinic in South Africa study [16]. The burden of disease in
South Africa is in the process of profound health transi-
tions where communicable and non-communicable
disorders coexist, and where chronic conditions such as
cardiovascular disease, type 2 diabetes, cancer, chronic
lung disease and depression are all predicted to increase
substantially [17].
Treatment of depression is vital to improved adher-
ence, social functioning and the disease course of
chronic conditions [5, 14, 18, 19]. Early recognition and
appropriate management of depression has the potential
to improve adherence and impact on the social function-
ing and the disease progression of chronic conditions,
thereby enhancing quality of life [5, 9, 18–20].
While identifying depressive disorder in primary care
is recognized as important to effective treatment, only
about half of patients with depressive disorder are
detected by regular health care providers in high-income
settings [21, 22]. In South Africa, this gap is far greater,
with only one in four people with a common mental
disorder receiving treatment [23]. With HIV transition-
ing to a chronic condition as a function of the roll-out
of anti-retroviral treatment (ART) in South Africa, as
well as the rising burden of NCDs (Non Communicable
Diseases), which includes mental disorders [17], there is
an imperative to integrate the treatment of depression
with chronic disease management.
In the context of busy primary health care (PHC)
clinics, the use of valid screening tools that facilitate
assessment of depression by non-specialists would allow
for greater depression detection and care, as well as
being in line with the task-sharing model that has been
embraced by the recent National Mental Health Policy
Framework and Strategic Action Plan (2013–2020) in
South Africa [24]. The Patients Health Questionnaire
(PHQ-9) is a brief diagnostic and severity measure of
depression, which has been widely used in research and
clinical practice but has not been validated for use in
South Africa on chronic care patients.
While there are numerous studies that report on the
validity of the PHQ-9 in relation to various chronic
illnesses, most of these studies fail to use an appropriate
reference standard to evaluate the performance of the
PHQ-9′s performance in identifying depression [25–28].
Only a few studies involving patients in chronic care
have examined the PHQ-9 against a criterion standard.
The PHQ-9 successfully screened post-stroke depression
patients with operating characteristics similar or
superior to other depression measures [29]. Similar
findings are noted in the Heart and Soul study of
depression among patients with coronary heart disease
[30]. A meta-analysis that included chronic care condi-
tions involving patients from cardiology, renal dialyses,
brain injury and stroke facilities as well as general
medical outpatients found the PHQ-9 acceptable as a
diagnostic screening tool for major depression [31].
In sub-Saharan Africa, only a few studies have estab-
lished the criterion validity of the PHQ-9 as a screening
tool for depression [16, 26, 32, 33]. A meta-analysis
establishing the range of optimal cut-off scores for diag-
nosing depression with the PHQ-9 notes that optimal
cut-off scores range between 8 and 11 [34]. In low and
middle income contexts, a positive screen for depression
was defined as a score of ≥10 [32, 35].
This study aimed to validate the PHQ-9 as a screening
tool for depression among chronic care patients attend-
ing two public primary health care facilities in South
Africa. As a secondary objective, we validated the PHQ-
2 - a subset of two questions drawn from the PHQ-9 –
which is a simpler screening option that has been
validated elsewhere [36]. The PHQ-2 has not been vali-
dated against a gold standard in sub-Saharan Africa,
though it has been recommended as a valid and reliable
tool for use in resource-constrained settings [28].
Methods
Setting and participants
The study was conducted in two primary health care
clinics in the North West province of South Africa. The
two clinics are pilot sites for a national Department of
Health model for integrated chronic disease manage-
ment, which adopts the collaborative chronic care model
and services all chronic care patients at one service
point [37].
Study procedures
This validation study was nested within a larger facility
detection survey designed to assess the detection and
treatment of depression and alcohol use disorders by
health care providers for adult attendees of primary
health clinics. Patients who had come to the chronic
care clinic were recruited from the consultation waiting
room before their consultation with a clinician. In the
waiting room, a field worker asked for volunteers to take
part in a survey on depression and alcohol use disorders.
The field worker directed interested individuals to a
research assistant in a private consultation room. The
research assistants who were recruited from the local
communities had completed secondary school, were
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fluent in seTswana and English, and were trained in
administering the PHQ-9 by a clinical psychologist. The
research assistant assessed the patients for inclusion
criteria, which were: age 18 years or older, clinic attend-
ance for routine chronic disease services (e.g., HIV,
hypertension, diabetes) and ability to comprehend and
complete study components in seTswana or English.
Exclusion criteria included incapacity to provide informed
consent (e.g., less than 18 years of age, presence of severe
intellectual disability or currently experiencing an acute
medical issue, or in treatment for major depression).
Eligible patients provided written informed consent to
participate in the validation study. Patients with low levels
of literacy could sign the informed consent form with an
“X” after discussing the study with a study supervisor, and
having the consent form read out to them.
Research assistants who administered the PHQ-9 were
supervised by mid-level psychological counsellors with
4-year Bachelor’s degrees in psychology who were fluent
in seTswana and trained by the seTswana-speaking clin-
ical psychologist in the administration of the PHQ-9.
These research assistants then orally administered the
PHQ-9 screening tool, and entered the participant’s
responses in a questionnaire application programmed
onto a mobile handheld device [38]. In addition to the
PHQ-9 screening instrument, the interview contained
questions on socio-demographic characteristics, eco-
nomic status, chronic care services received at the clinic,
alcohol use and disability status as part of the larger
study. Immediately after the conclusion of the screening
interview, the research assistant directed the participant
to another private consultation room for the diagnostic
interview with a clinical psychologist. The research
assistant did not appraise the participant or the psych-
ologist of the participant’s PHQ-9 screening score. In
each clinic, a clinical psychologist conducted the
Structured Clinical Interview for DSM-IV (SCID) [39]
diagnostic interview for a current episode of depressive
disorder. One psychologist was fluent in both study
languages, while the other was assisted by a seTswana-
speaking mid-level trained psychological counsellor to
conduct the diagnostic interviews. Most patients chose
to have the interviews in seTswana with only a few who
chose to be interviewed in English. At the conclusion of
the diagnostic interview, any patient who 1) expressed
suicidality (i.e. thoughts, plans, actions); or 2) was judged
to have severe symptoms of depression by the clinical
psychologist, was asked by the research assistant to pro-
vide consent for a referral to the consulting nurse in the
clinic.
Ethical approval for the validation study was obtained
from the University of KwaZulu-Natal Biomedical Re-
search Ethics Committee (BE271/13). Ethical approval
for the larger study was obtained from the University of
KwaZulu-Natal Biomedical Research Ethics Committee
(BE400/13), and the University of Cape Town, Faculty of
Health Sciences, Human Research Ethics Committee
(412/2011), and the World Health Organization
Research Ethics Review Committee (RPC497).
Assessments
The PHQ-9 asks patients to rate how often they were
bothered by specific problems over the last two weeks.
Each item is scored from 0 to 3 (0 = not at all; 1 = several
days; 2 =more than half the days; and 3 = nearly every
day) [36]. All nine items in the PHQ-9 are derived from
DSM-IV criteria relevant for diagnosis of a current depres-
sive episode [21]. The PHQ-2 is comprised of the first two
questions of the PHQ-9, namely whether the patient has
depressed mood and loss of interest (anhedonia). The
PHQ-9 asks patients to rate how often they were bothered
by specific problems over the last two weeks. Each item is
scored from 0 to 3 according to the frequency of the prob-
lem. After a piloting process we adapted the response set
to improve respondent understanding, such that “several
days” was understood to be 1–7 days, “half the days” was
understood to be 8–11 days and “nearly every day” was
understood to be 12–14 days, as was the case in other
validity studies in Africa [16, 26]. The PHQ-9 was trans-
lated into seTswana by a seTswana-speaking mental health
professional and then back-translated by an independent
seTswana-speaking clinical psychologist using the method-
ology described by Brislin [40] (Additional file 1). Due to
time considerations and the logistics of administering the
PHQ-9 twice to a clinic population, test-retest reliability
was not done. Inter-rater reliability was also not com-
pleted for the same reasons.
The gold standard diagnostic interview was the de-
pression module of the SCID-I to assess the participants
for the presence or absence of major depressive disorder.
The SCID is a semi-structured interview administered
by a trained clinician who assesses a respondent for the
presence or absence of a mental health disorder. At the
time of the study, the more recent version of the SCID
was not available. Nevertheless, the criteria for depres-
sion remains the same in the DSM-V as the DSM-IV
version. According to the American Psychiatric Associ-
ation “neither the core criterion symptoms applied to
the diagnosis of major depressive episode nor the
requisite duration of at least 2 weeks has changed from
DSM-IV. Criterion A for a major depressive episode in
DSM-V is identical to that of DSM-IV, as is the requirement
for clinically significant distress or impairment in social,
occupational, or other important areas of life” (p. 4) [41].
Sample characteristics
Out of a total of 1321 eligible patients who participated
in the larger facility survey, 1025 patients were attendees
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of the clinics where the validation study was conducted.
Of these patients, a sub-sample of 676 patients partici-
pated in the validation study between February and April
2014. Participants who consented to the general study
also consented to the PHQ9 validation study. The
sub-sample size was limited by the availability of the
clinical psychologists to conduct diagnostic interviews.
Overall, there were 233 refusals to the larger study.
Table 1 reflects the demographic characteristics of the
676 participants who completed both the SCID and
PHQ-9 interviews. The participants were predominantly
female (75.0 %), with mean age of 47.1 years (SD 13.1).
Most participants (72.4 %) had completed 6 or more
years of primary education. Participants could report
multiple conditions for which they had been diagnosed
and for which they were receiving services. The most
common conditions reported were HIV infection
(61.1 %), hypertension (51.0 %), diabetes (9.3 %), and
tuberculosis (4.9 %). Of the 413 participants diagnosed
with HIV and 345 patients diagnosed with hypertension,
118 participants were found to be co-morbid.
Data analyses
First, we described the socio-demographic and clinical
characteristics of participants recruited for this valid-
ation study and proportion of patients receiving a
depression diagnosis on the SCID. We evaluated the
internal consistency of the PHQ-9 by calculating the
Cronbach alpha. Next, we used the screening scores
from the PHQ-9 interview to construct a receiver oper-
ating characteristic (ROC) curve and calculated the area
under the ROC (AUROC) using the SCID as the gold
standard. The AUROC provides a summary measure of
a screening tool’s sensitivity and specificity, relative to
the gold standard diagnostic, across the entire range of
screening scores. An AUROC score of 0.5 is consistent
with a screening tool that is no better than chance, and
a score of 1.0 indicates a perfectly accurate screening
tool. We also calculated the AUROC for the PHQ2 and
compared it to the AUROC for the PHQ-9. To explore
potential heterogeneity of the validity of the PHQ-9, we
also repeated the AUROC analysis with two (overlapping)
subsets of participants who reported that their clinic
attendance was for ongoing care with HIV infection and
with hypertension. For all AUROC calculations, we report
exact binomial 95 % confidence intervals (95 % CI).
We completed all analyses using Stata 13.1 (StataCorp,
College Station, USA); we used the ‘roctab’ command for
analysis of the individual AUCs, and ‘roccomp’ for the
comparison of the PHQ-9 and the PHQ-2.
Results
Descriptive results
In the SCID diagnostic interview, more than one in ten
(11.47 %) participants were diagnosed as currently
experiencing a major depressive episode. The mean PHQ-
9 score for those who were SCID-positive (PHQ-9 score
9.4, SD 5.3) was substantially higher than for those who
were SCID-negative (PHQ-9 score 3.2, SD 3.1). For those
with an HIV diagnosis, 12.6 % were SCID-positive, while
9.9 % of those with hypertension were also SCID-positive.
No participant experienced any adverse events during
either interview. The study psychologist referred 69
participants to the clinic on-call nurse, following disclosure
of suicidal ideation, planning or attempts (Table 2).
Internal consistency of the PHQ-9 revealed a Cronbach
alpha of 0.76.
Table 1 Demographic and clinical characteristics chronic care
patients (n = 676) in North West Province, South Africa
Description n (%)
Sex
Male 169 (25.0)
Female 507 (75.0)
Age (years)
Median 47 IQR 37–56.5
Range 18–88
Education
None 52 (7.7)
Grades 1–5 135 (20.0)
Grades 6–12 478 (70.7)
>12 years 11 (1.6)
Chronic care servicea
HIV/AIDS 413 (61.1)
Hypertension 345 (51.0)
Diabetes 63 (9.3)
Tuberculosis 33 (4.9)
Asthma 24 (3.6)
Epilepsy 23 (3.4)
Arthritis 23 (3.4)
Other Mental Healthb 17 (2.5)
Heart problems 6 (0.9)
Chronic obstructed pulmonary disorder 2 (0.30)
Number of chronic care services
1 399 (59.0)
2 237 (35.1)
3 38 (5.3)
> = 4 2 (0.3)
IQR interquartile range
aParticipants can report >1 chronic service, total is >100 %
bFor example, Schizophrenia and Bipolar Mood Disorders
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Fig. 1 Receiver operating characteristic (ROC) curve for PHQ-9
Table 2 Performance of the PHQ-9 and PHQ-2 to detect major depressive disorder among chronic care patients (n = 676)
PHQ-9 PHQ-2
Cut point Sensitivity (%) Specificity (%) Correctly classified (%) LR + a LR-b Sensitivity (%) Specificity (%) Correctly classified (%)
(≥0) 100.0 0.0 11.4 1.000 100.0 0.0 11.4
(≥1) 100.0 21.4 30.3 1.2718 0.0000 80.5 57.9 60.5
(≥2) 97.4 37.1 43.9 1.5476 0.0701 59.7 83.5 80.8
(≥3) 90.9 52.4 56.8 1.9107 0.1734 39.0 91.7 85.7
(≥4) 87.0 63.3 66.0 2.3691 0.2053 19.5 97.8 88.9
(≥5) 80.5 71.8 72.8 2.8539 0.2714 9.1 99.3 89.1
(≥6) 71.4 79.1 78.2 3.4229 0.3611 0.0 100.0 88.6
(≥7) 64.9 85.6 83.3 4.5228 0.4094
(≥8) 53.2 90.6 86.4 5.6955 0.5157
(≥9) 49.3 93.7 88.6 7.7792 0.5408
(≥10) 41.6 96.5 90.2 11.8540 0.6056
(≥11) 36.4 98.2 91.1 19.8016 0.6483
(≥12) 32.5 98.5 91.0 21.6090 0.6856
(≥13) 26.0 98.5 90.2 17.2872 0.7516
(≥14) 24.7 98.8 90.4 21.1150 0.7622
(≥15) 19.5 99.5 90.4 38.8963 0.8092
(≥16) 14.3 99.7 89.9 42.7863 0.8600
(≥17) 9.1 99.7 89.4 27.2276 0.9121
(≥19) 9.1 99.4 89.5 54.4541 0.9106
(≥20) 3.9 99.8 88.9 23.3375 0.9626
(≥21) 2.6 99.8 88.8 15.5583 0.9757
(≥22) 1.3 100.0 88.8 0.9870
(≥22) 0.0 100.0 88.6 1.0000
The SCID depression module was used as the diagnostic reference standard
aLikelihood Ratio Positive
bLikelihood Ratio Negative
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Sensitivity and specificity of the PHQ-9 and PHQ-2
With the full study sample, the PHQ-9 showed reason-
ably high validity (AUROC 0.85, 95 % CI 0.82–0.88).
With a cut point of ≥9, the PHQ-9 had sensitivity of
49 % and specificity of 94 %. The likelihood ratio of a
person testing positive for depression was seven times
more likely at this cut point (7.7792). The Overall Cor-
rect Classification (OCC) rate of 0.886 was also the best
at a cutoff of 9 and above. With this cut point, the positive
and negative predictive values were 50 % and 94 %, respect-
ively. Youden’s Index (Youden’s J) identifies a cut point
of ≥5, with a maximum value of sensitivity- (1-specificity)
of 52.3 %.
The validity of the PHQ-9 was similar for the subsam-
ples of 413 patients receiving services for HIV infection
(AUROC 0.85, 95 % CI 0.81–0.88) and the 345 patients
receiving services for hypertension (AUROC 0.85, 95 %
CI 0.82–0.90).
While the PHQ-2 appeared to be a valid screening tool
(AUROC 0.76, 95 % CI 0.73–0.79), its AUROC was sig-
nificantly lower than for the PHQ-9 (p < 0.0001). With a
cut point of ≥2, the PHQ-2 had sensitivity of 60 % and
Fig. 3 Receiver operating characteristic (ROC) curve comparing PHQ-9 to PHQ-2
Fig. 2 Receiver operating characteristic (ROC) curve for PHQ-2
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specificity of 84 %, correctly classifying 81 % of the popu-
lation at this level (Figs. 1, 2 and 3, Tables 3, 4 and 5).
Discussion
The health care burden associated with the burgeoning
chronic care population in South Africa makes this a
timely and important focus as individuals with depres-
sion are less likely to be treatment adherent or engage in
health enhancing behavior change to promote healthy
lifestyles [5, 18–20]. Given that identifying depression in
chronic care patients can be a diagnostic challenge in
busy clinics, a short and valid screening tool can assist
in the identification of patients with depression.
A meta-analysis establishing the range of optimal cut-
off scores for diagnosing depression with the PHQ-9
notes that optimal cut-off scores range between 8 and
11 [34]. In this study, a cut-point of ≥9 yielded a fairly
low sensitivity (49 %) in comparison to sensitivity indices
of 78.7 % and 89.6 %, respectively in other similar valid-
ity studies in sub-Saharan Africa [16, 32], However,
higher specificity (94 %) was noted in the present study
Table 4 Performance of the PHQ-9 in Detecting Depression
in HIV positive patients (n = 413) in North West Province,
South Africa
Cut-point Sensitivity
%
Specificity
%
Percent
correctly
classified
LR+ LR-
(≥0) 100.00 0.00 12.59 1.000
(≥1) 100.00 21.05 30.99 1.2667 0.0000
(≥2) 98.08 33.80 41.89 1.4814 0.0569
(≥3) 88.46 49.31 54.24 1.7451 0.2340
(≥4) 84.26 61.22 64.16 2.1819 0.2513
(≥5) 82.69 68.42 70.22 2.6186 0.2530
(≥6) 76.92 77.29 77.24 3.3865 0.2986
(≥7) 71.15 83.93 82.32 4.4287 0.3437
(≥8) 57.69 88.92 84.99 5.2067 0.4758
(≥9) 57.69 92.80 88.38 8.0104 0.4559
(≥10) 48.08 95.57 89.59 10.4874 0.5433
(≥11) 40.38 97.51 90.31 16.1987 0.6114
(≥12) 36.54 98.06 90.31 18.8434 0.6472
(≥13) 28.85 98.06 89.35 14.8764 0.7256
(≥14) 26.92 98.61 89.59 19.4385 0.7410
(≥15) 23.08 99.45 89.83 41.6359 0.7735
(≥16) 17.31 99.72 89.35 62.4808 0.8292
(≥19) 11.54 99.72 88.62 41.6539 0.8871
(≥20) 5.77 99.72 87.89 20.8269 0.9449
(≥21) 3.85 99.72 87.65 13.8846 0.9642
(≥22) 1.92 100 87.65 0.9808
(≥22) 0.00 100 87.41 1.0000
Observations ROC Area under
the curve
Std. Error 95 % Confidence
Interval
413 0.8488 0.0293 0.81 0.88
Table 5 Performance of the PHQ-9 in Detecting Depression in
Patients with hypertension (n = 345) in North West Province,
South Africa
Cut-point Sensitivity
%
Specificity
%
Percent
correctly
classified
LR+ LR-
(≥0) 100.00 0.00 9.86 1.000
(≥1) 100.00 20.58 28.41 1.2591 0.0000
(≥2) 97.06 37.03 43.19 1.5408 0.0789
(≥3) 97.06 51.77 56.23 2.0124 0.0568
(≥4) 91.18 62.38 65.22 2.4236 0.1414
(≥5) 79.41 72.35 73.04 2.8718 0.2846
(≥6) 67.65 80.39 79.13 3.4489 0.4025
(≥7) 64.71 85.85 83.77 4.5735 0.4111
(≥8) 52.94 91.96 88.12 6.5859 0.5117
(≥9) 44.12 94.53 89.57 8.0709 0.5911
(≥10) 38.42 98.07 92.17 19.8186 0.6298
(≥11) 32.35 99.36 92.75 50.3086 0.6808
(≥12) 29.41 99.36 92.46 45.7351 0.7105
(≥14) 23.53 99.36 91.88 36.5881 0.7697
(≥15) 17.65 99.68 91.59 51.8828 0.8262
(≥16) 11.76 99.68 91.01 36.5885 0.8852
(≥17) 8.82 99.68 90.72 27.4414 0.9147
(≥19) 8.82 100 91.01 0.9118
(≥20) 2.94 100 90.43 0.9706
(≥20) 0.00 100 90.14 0.9706
Observations ROC Area under
the curve
Std. Error 95 % Confidence
Interval
345 0.8596 0.0309 0.82 0.90
Table 3 Item-level discrimination PHQ-9 (N = 676)
Item Item-test correlation Item-rest
correlation
Average Inter-item
covariance
Item
Alpha
Phq1 0.578 0.429 0.144 0.734
Phq2 0.649 0.491 0.133 0.724
Phq3 0.619 0.440 0.135 0.734
Phq4 0.655 0.509 0.133 0.721
Phq5 0.620 0.451 0.135 0.732
Phq6 0.602 0.465 0.142 0.723
Phq7 0.587 0.466 0.147 0.730
Phq8 0.347 0.250 0.170 0.757
Phq9 0.546 0.420 0.150 0.736
Overall 0.143 0.756
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relative to the only other South African study (83.4 %)
[16] and was the same as that found for HIV patients in
Cameroon [26]. A prospective study of psychosocial
factors and health outcomes in patients with a diagnosis
of coronary heart disease also showed similar sensitivity
and specificity to the present study [30].
Similar to the PHQ-9, the PHQ-2 had lower sensitivity
(60 %) than specificity (84 %) and may be explained in
the same way as that for the PHQ-9 given that these
data are drawn from the same sample. The PHQ-2
remains a valid option for use, particularly in time-
constrained settings. The trade-off between sensitivity
and specificity using the PHQ-2 is more substantial than
for the PHQ-9. Selecting a high cut-off score when using
the PHQ-2 would enable clinicians to screen a large
number of patients, but then to refer a relatively modest
number of patients – who are likely true cases - for
confirmation of a diagnosis of depression.
The strength of this study is that it is one of the few
studies to consider the validity of the PHQ-9 in sub-
Saharan Africa, and the first to validate the PHQ-9 or
the PHQ-2 for a chronic care population in South
Africa. Limitations of this study include that the partici-
pants were drawn from only two clinics in North West
province, and were predominantly female. Therefore, it
may not be possible to generalize our results to other
populations. We were unable to establish test-retest
reliability due to time considerations and the burden it
would impose on the public health clinics. On the same
basis, we were unable to establish inter-rater reliability
of administration of the gold standard instrument. For
logistic reasons we were also unable to randomize the
order of interviews as participants with depression
would be more likely to be detected in the diagnostic
interview than in the screening interview. Further, a
willingness to disclose feelings of distress in the diagnos-
tic interview may have been heightened after completing
the screening interview. This ‘order’ effect may have
biased our AUROC results to be lower than the true
values.
Conclusions
The brevity of the scale, ease of administration and its
concurrent validity with the SCID suggests that the
PHQ-9 can be a valuable instrument for identifying co-
morbid depression in patients with chronic conditions
using a cut-point of ≥9. It is possible that the abbreviated
PHQ-2 could be used in a busy primary care clinic, but
would need to be followed up with a full assessment.
Identification is the first step towards closing the
treatment gap for depression and advancing the agenda
of integrated chronic disease management in South
African public health facilities. Further research is
needed in understanding how patients with low levels of
understanding of depression as a legitimate disorder and
recognition of depressive symptoms are likely to respond
to screening tools such as the PHQ-9.
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